Duygu Temiz Karadag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Duygu Temiz Karadag has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
26 shared publications - Ayten Yazici
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey
25 shared publications - Ozlem Ozdemir Isik
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey
11 shared publications - Neslihan Gokcen
Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sakarya University, Sakarya, Türkiye
10 shared publications Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, İzmit, Turkey
8 shared publicationsAyten Yazici
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, İzmit, Turkey
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Arthritis Care & Research
Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Objectives: We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD). Methods: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc‐ILD initiated an eligible ILD‐modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone‐equivalent dose ≤20 mg/day). Follow‐up ended at the visit closest to 12 months within a 9 to 15‐month window. The primary outcome was the between‐group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. Results: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD‐modifying therapy and 258 (58.2%) received ILD‐modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12‐month FVC. The adjusted mean difference in FVC change was ‐2.10 percentage points (95% CI ‐4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated‐weight sensitivity analysis. Conclusion: Adding oral glucocorticoids to ILD‐modifying therapy was not associated with improved 12‐month FVC in SSc‐ILD. Secondary outcomes were sparse and should be interpreted cautiously. image
- 11 November 2026
- Published by Wiley in Arthritis Care & Research
Open AccessOral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Objectives: We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD). Methods: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc‐ILD initiated an eligible ILD‐modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone‐equivalent dose ≤20 mg/day). Follow‐up ended at the visit closest to 12 months within a 9 to 15‐month window. The primary outcome was the between‐group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. Results: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD‐modifying therapy and 258 (58.2%) received ILD‐modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12‐month FVC. The adjusted mean difference in FVC change was ‐2.10 percentage points (95% CI ‐4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated‐weight sensitivity analysis. Conclusion: Adding oral glucocorticoids to ILD‐modifying therapy was not associated with improved 12‐month FVC in SSc‐ILD. Secondary outcomes were sparse and should be interpreted cautiously. image
- Open Access
- 15 September 2026
- Published by Wiley in Arthritis & Rheumatology
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Objective: Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods: We performed a nested case‐control study within the European Scleroderma Trials and Research group: “cases” were defined as patients with SSc who developed cancer at any time point; controls were patients with SSc who were cancer free, matched for age and disease duration. Malignancies were classified as “synchronous” to SSc onset (±3 years), “subsequent” (more than three years after), or “previous” (more than three years before). Clinical, serologic, and treatment associations, as well as survival rates, were analyzed. Results: A total of 454 patients with SSc with cancer (29% synchronous, 51% subsequent, 20% previous) and 454 controls were identified. Mean age was 55 ± 13 years, disease duration was 5 ± 2 years; 88% were female, and 27.5% had diffuse SSc; 30.5% had interstitial lung disease (ILD), 32% had anti‐topoisomerase, and 10% had anti‐POLR3. Synchronous cancers were associated with anti‐POLR3 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.13–3.69), U1RNP (OR 3.56, 95% CI 1.03–12.3), and smoking (OR 1.57, 95% CI 1.01–2.44), but they were negatively associated with digital ulcers (OR 0.55, 95% CI 0.31–0.93). Calcinosis was inversely associated with subsequent cancers (OR 0.42, 95% CI 0.17–0.93). Breast cancer showed time‐dependent associations with anti‐POLR3 and anti‐PM/Scl; lung cancer was mainly subsequent and associated with ILD (OR 2.00, 95% CI 1.12–3.54), anti‐topoisomerase (OR 2.61, 95% CI 1.38–5.04), and smoking. Cancers occurred more frequently in patients treated with cyclophosphamide. Malignancy worsened overall survival, particularly when subsequent. Radiation therapy did not impact mortality rate or new‐onset ILD. Conclusion: Cancer timing and site identify distinct clinical‐serologic associations in SSc, with different prognostic implications. As cancers diagnosed during follow‐up are major determinants of death, our findings inform the implementation of stratified cancer surveillance in SSc. image
- 15 September 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessCancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Objective: Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods: We performed a nested case‐control study within the European Scleroderma Trials and Research group: “cases” were defined as patients with SSc who developed cancer at any time point; controls were patients with SSc who were cancer free, matched for age and disease duration. Malignancies were classified as “synchronous” to SSc onset (±3 years), “subsequent” (more than three years after), or “previous” (more than three years before). Clinical, serologic, and treatment associations, as well as survival rates, were analyzed. Results: A total of 454 patients with SSc with cancer (29% synchronous, 51% subsequent, 20% previous) and 454 controls were identified. Mean age was 55 ± 13 years, disease duration was 5 ± 2 years; 88% were female, and 27.5% had diffuse SSc; 30.5% had interstitial lung disease (ILD), 32% had anti‐topoisomerase, and 10% had anti‐POLR3. Synchronous cancers were associated with anti‐POLR3 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.13–3.69), U1RNP (OR 3.56, 95% CI 1.03–12.3), and smoking (OR 1.57, 95% CI 1.01–2.44), but they were negatively associated with digital ulcers (OR 0.55, 95% CI 0.31–0.93). Calcinosis was inversely associated with subsequent cancers (OR 0.42, 95% CI 0.17–0.93). Breast cancer showed time‐dependent associations with anti‐POLR3 and anti‐PM/Scl; lung cancer was mainly subsequent and associated with ILD (OR 2.00, 95% CI 1.12–3.54), anti‐topoisomerase (OR 2.61, 95% CI 1.38–5.04), and smoking. Cancers occurred more frequently in patients treated with cyclophosphamide. Malignancy worsened overall survival, particularly when subsequent. Radiation therapy did not impact mortality rate or new‐onset ILD. Conclusion: Cancer timing and site identify distinct clinical‐serologic associations in SSc, with different prognostic implications. As cancers diagnosed during follow‐up are major determinants of death, our findings inform the implementation of stratified cancer surveillance in SSc. image
- 14 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70871
Case Report: Serum Protein Electrophoresis Incidentally Reveals Alpha‐1 Antitrypsin Deficiency in p‐ ANCA ‐Positive Crescentic Glomerulonephritis
- 14 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70871
Case Report: Serum Protein Electrophoresis Incidentally Reveals Alpha‐1 Antitrypsin Deficiency in p‐ ANCA ‐Positive Crescentic Glomerulonephritis
- 4 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (9) , 251
Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study
- 4 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (9) , 251
Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study
- 29 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6103-6113
Longitudinal changes in renal function in rheumatoid arthritis patients treated with biologic agents: a retrospective cohort study
- 29 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6103-6113
Longitudinal changes in renal function in rheumatoid arthritis patients treated with biologic agents: a retrospective cohort study
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- Open Access
- 9 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (4) , 76
Validation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis
Subclinical and overt inflammatory bowel disease (IBD) is frequently observed in patients with axial spondyloarthritis (ax-SpA), traditionally identified through invasive ileocolonoscopic evaluation. Validated non-invasive assessing instruments are therefore needed to facilitate early detection. This study aimed to validate the Turkish version of the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) as a tool for assessing gastrointestinal symptom burden suggestive of intestinal involvement in patients with axial spondyloarthritis. In this cross-sectional validation study, 174 patients fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA were enrolled. Convergent validity was assessed by examining correlations between DISQ scores and disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), functional status (Bath Ankylosing Spondylitis Functional Index [BASFI]), and health-related quality of life (Short Form-36 [SF-36]). Discriminant validity was evaluated by comparing DISQ scores in patients with and without gastrointestinal symptoms suggestive of IBD. Test–retest reliability was assessed by re-administration of the DISQ after one month. Internal consistency was evaluated using Cronbach’s alpha. DISQ scores demonstrated moderate positive correlations with BASDAI (r = 0.432, p < 0.001) and BASFI (r = 0.248, p = 0.001), and a strong inverse correlation with SF-36 scores (p < 0.001), supporting convergent validity. Patients reporting diarrhea, abdominal pain, oral aphthae, or mucus in stool had significantly higher DISQ scores than those without these symptoms (all p ≤ 0.008), confirming discriminant validity. The Turkish version of the DISQ demonstrated acceptable internal consistency (Cronbach’s α = 0.70) and good test–retest reliability (ICC = 0.76; 95% CI: 0.51–0.82; p < 0.001). The Turkish version of DISQ demonstrates satisfactory validity and reliability as a non-invasive assessment instrument for gastrointestinal symptoms suggestive of bowel inflammation in patients with ax-SpA. Future studies incorporating endoscopic and biomarker-based outcomes are warranted to define clinically meaningful cut-off values and determine its role in routine clinical practice.
- 9 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (4) , 76
Open AccessValidation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis
Subclinical and overt inflammatory bowel disease (IBD) is frequently observed in patients with axial spondyloarthritis (ax-SpA), traditionally identified through invasive ileocolonoscopic evaluation. Validated non-invasive assessing instruments are therefore needed to facilitate early detection. This study aimed to validate the Turkish version of the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) as a tool for assessing gastrointestinal symptom burden suggestive of intestinal involvement in patients with axial spondyloarthritis. In this cross-sectional validation study, 174 patients fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA were enrolled. Convergent validity was assessed by examining correlations between DISQ scores and disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), functional status (Bath Ankylosing Spondylitis Functional Index [BASFI]), and health-related quality of life (Short Form-36 [SF-36]). Discriminant validity was evaluated by comparing DISQ scores in patients with and without gastrointestinal symptoms suggestive of IBD. Test–retest reliability was assessed by re-administration of the DISQ after one month. Internal consistency was evaluated using Cronbach’s alpha. DISQ scores demonstrated moderate positive correlations with BASDAI (r = 0.432, p < 0.001) and BASFI (r = 0.248, p = 0.001), and a strong inverse correlation with SF-36 scores (p < 0.001), supporting convergent validity. Patients reporting diarrhea, abdominal pain, oral aphthae, or mucus in stool had significantly higher DISQ scores than those without these symptoms (all p ≤ 0.008), confirming discriminant validity. The Turkish version of the DISQ demonstrated acceptable internal consistency (Cronbach’s α = 0.70) and good test–retest reliability (ICC = 0.76; 95% CI: 0.51–0.82; p < 0.001). The Turkish version of DISQ demonstrates satisfactory validity and reliability as a non-invasive assessment instrument for gastrointestinal symptoms suggestive of bowel inflammation in patients with ax-SpA. Future studies incorporating endoscopic and biomarker-based outcomes are warranted to define clinically meaningful cut-off values and determine its role in routine clinical practice.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Rheumatology
- Vol. 2026 (1) , 4852681
Case Report: Secukinumab Experience in a Patient With Coexistence of Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Antiphospholipid Antibody Syndrome
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by autoantibody production and immune complex deposition. Antiphospholipid syndrome (APS) is frequently associated with SLE and is characterized by arterial or venous thrombosis and pregnancy morbidity in the presence of persistent antiphospholipid antibodies. The coexistence of ankylosing spondylitis (AS) with SLE and APS is extremely rare. A 38‐year‐old woman was admitted to our clinic with gangrene of the right fifth toe and swelling of both knees. She had a previous diagnosis of AS based on inflammatory low back pain and radiographic evidence of bilateral Grade 4 sacroiliitis. Laboratory investigations revealed positive antinuclear antibody, anti‐double‐stranded DNA, and antiphospholipid antibodies, including lupus anticoagulant and anti‐cardiolipin IgG. Renal biopsy performed due to proteinuria demonstrated mesangioproliferative lupus nephritis. Based on clinical, laboratory, and histopathological findings, the patient was diagnosed with coexisting AS, SLE, and APS. Considering the coexistence of these autoimmune diseases and the patient’s previous exposure to anti‐tumor necrosis factor therapy, treatment with the interleukin‐17 inhibitor secukinumab was initiated. The patient showed significant improvement in inflammatory back pain and arthritis during follow‐up. To our knowledge, this is one of the rare reported cases of coexistence of AS, SLE, and APS treated with secukinumab.
- 1 January 2026
- Published by Wiley in Case Reports in Rheumatology
- Vol. 2026 (1) , 4852681
Open AccessCase Report: Secukinumab Experience in a Patient With Coexistence of Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Antiphospholipid Antibody Syndrome
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by autoantibody production and immune complex deposition. Antiphospholipid syndrome (APS) is frequently associated with SLE and is characterized by arterial or venous thrombosis and pregnancy morbidity in the presence of persistent antiphospholipid antibodies. The coexistence of ankylosing spondylitis (AS) with SLE and APS is extremely rare. A 38‐year‐old woman was admitted to our clinic with gangrene of the right fifth toe and swelling of both knees. She had a previous diagnosis of AS based on inflammatory low back pain and radiographic evidence of bilateral Grade 4 sacroiliitis. Laboratory investigations revealed positive antinuclear antibody, anti‐double‐stranded DNA, and antiphospholipid antibodies, including lupus anticoagulant and anti‐cardiolipin IgG. Renal biopsy performed due to proteinuria demonstrated mesangioproliferative lupus nephritis. Based on clinical, laboratory, and histopathological findings, the patient was diagnosed with coexisting AS, SLE, and APS. Considering the coexistence of these autoimmune diseases and the patient’s previous exposure to anti‐tumor necrosis factor therapy, treatment with the interleukin‐17 inhibitor secukinumab was initiated. The patient showed significant improvement in inflammatory back pain and arthritis during follow‐up. To our knowledge, this is one of the rare reported cases of coexistence of AS, SLE, and APS treated with secukinumab.
- Open Access
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1341-1343
Validation of the Turkish version of the assessment of systemic sclerosis-associated Raynaud’s phenomenon (ASRAP)
By DUYGU TEMİZ KARADAĞ, ŞEYMA YILMAZ, BETÜL DİKKANOĞLU DEMİROK, et al., Published on 10/14/25
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1341-1343
Open AccessValidation of the Turkish version of the assessment of systemic sclerosis-associated Raynaud’s phenomenon (ASRAP)
By DUYGU TEMİZ KARADAĞ, ŞEYMA YILMAZ, BETÜL DİKKANOĞLU DEMİROK, et al., Published on 10/14/25
- 8 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (8) , 187
Approaches to screening for rheumatoid arthritis-associated interstitial lung disease: a cross-sectional national survey of Turkish rheumatologists
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening complication of RA, yet standardized screening guidelines are lacking. This study aimed to explore current screening practices among Turkish rheumatologists and assess how demographic and institutional factors influence clinical decision-making. An electronic survey was distributed to 550 members of the Turkish Society for Rheumatology between May and June 2024. The questionnaire included items on respondents' clinical experience, practice settings, estimated RA-ILD prevalence, screening criteria, and preferred diagnostic methods. A total of 107 rheumatologists completed the survey (response rate: 20%). Most participants (59.8%) worked in university hospitals and 44.9% had ≤ 5 years of clinical experience. Over half (52.3%) estimated the frequency of RA-ILD in their patients to be 5-10%. Nearly half of the rheumatologists (47.7%) screened RA patients with respiratory symptoms. The three most frequently used screening methods were chest computed tomography (CT) (77.6%), chest X-ray (72.9%), and pulmonary function testing (PFT) (65.4%). While 20% of participants reported using only a single method for screening, the most preferred combination was chest X-ray, CT, PFT, and diffusing capacity of the lungs for carbon monoxide (DLCO), used by 20.6% of respondents. Compared to university hospitals, rheumatologists working in state hospitals reported fewer opportunities for pulmonary assessments, limited access to DLCO testing, less collaboration with experienced radiologists or pulmonologists, and a lack of multidisciplinary approaches. Our study highlights the variability in disease assessment and clinical practices related to RA-ILD screening among rheumatologists. These findings underscore the need to standardize screening strategies, taking into account national healthcare conditions and the local working environments of rheumatologists.
- 8 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (8) , 187
Approaches to screening for rheumatoid arthritis-associated interstitial lung disease: a cross-sectional national survey of Turkish rheumatologists
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening complication of RA, yet standardized screening guidelines are lacking. This study aimed to explore current screening practices among Turkish rheumatologists and assess how demographic and institutional factors influence clinical decision-making. An electronic survey was distributed to 550 members of the Turkish Society for Rheumatology between May and June 2024. The questionnaire included items on respondents' clinical experience, practice settings, estimated RA-ILD prevalence, screening criteria, and preferred diagnostic methods. A total of 107 rheumatologists completed the survey (response rate: 20%). Most participants (59.8%) worked in university hospitals and 44.9% had ≤ 5 years of clinical experience. Over half (52.3%) estimated the frequency of RA-ILD in their patients to be 5-10%. Nearly half of the rheumatologists (47.7%) screened RA patients with respiratory symptoms. The three most frequently used screening methods were chest computed tomography (CT) (77.6%), chest X-ray (72.9%), and pulmonary function testing (PFT) (65.4%). While 20% of participants reported using only a single method for screening, the most preferred combination was chest X-ray, CT, PFT, and diffusing capacity of the lungs for carbon monoxide (DLCO), used by 20.6% of respondents. Compared to university hospitals, rheumatologists working in state hospitals reported fewer opportunities for pulmonary assessments, limited access to DLCO testing, less collaboration with experienced radiologists or pulmonologists, and a lack of multidisciplinary approaches. Our study highlights the variability in disease assessment and clinical practices related to RA-ILD screening among rheumatologists. These findings underscore the need to standardize screening strategies, taking into account national healthcare conditions and the local working environments of rheumatologists.